94193-77-8

Upstream product

• 79-04-9 chloroacetyl chloride 
• 20989-17-7 Phenylglycinol 
• 20989-17-7 (2S)-2-phenylglycinol 

Downstream Products

• 183988-03-6 N-((R)-2-Hydroxy-1-phenyl-ethyl)-2-(2-oxo-2-phenyl-ethylsulfanyl)-acetamide 
• 192815-71-7 (5R)-5-phenylmorpholin-3-one 
• 138713-44-7 3-(-)-Phenyl morpholine 
• 94193-80-3 (R,R)-7,13-bis(5-hydroxy-2-oxo-4-phenyl-3-azapentyl)-1,4,10-trioxa-7,13-diazacyclopentadecane 
• 1260672-03-4 5-phenylmorpholin-3-one 

Relevant academic research and scientific papers

TRICYCLIC MODULATORS OF TNF SIGNALING

The invention provides tricyclic heterocyclic compounds, pharmaceutically acceptable salts, prodrugs, biologically active metabolites, stereoisomers and isomers thereof wherein the variables are defined herein. The compounds of the invention may be useful for treating immunological and oncological conditions.

GLYCINE B ANTAGONISTS

The invention relates to naphthalene derivatives as well as their pharmaceutically acceptable salts. The invention further relates to a process for the preparation of such compounds. The compounds of the invention are glycine B antagonists and are therefore useful for the control and prevention of various disorders, including neurological disorders.

Substituted monocyclic CGRP receptor antagonists

Compounds of formula I: (wherein variables A1, A2, A3, A4, m, n, J, Q, R4, Ea, Eb, Ec, R6, R7, Re, Rf, RPG and Y are as described herein) which are antagonists of CGRP receptors and which are useful in the treatment or prevention of diseases in which the CGRP is involved, such as migraine. The invention is also directed to pharmaceutical compositions comprising these compounds and the use of these compounds and compositions in the prevention or treatment of such diseases in which CGRP is involved.